PriceTargets.com logo

NASDAQ:ABCL - AbCellera Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.80
  • Forecasted Upside: 77.06 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$29.82 As of 04/16/2021 01:00 AM ET
▲ +0.82 (2.83%)
1 month | 3 months | 12 months
Get New AbCellera Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABCL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$52.80
▲ +77.06% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AbCellera Biologics in the last 3 months. The average price target is $52.80, with a high forecast of $59.00 and a low forecast of $45.00. The average price target represents a 77.06% upside from the last price of $29.82.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in AbCellera Biologics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021SVB LeerinkLower Price TargetIn-Line ➝ Outperform$52.00 ➝ $45.00Medium
i
Rating by P. Souda at SVB Leerink LLC
3/30/2021Stifel NicolausLower Price TargetBuy$59.00 ➝ $55.00Medium
i
3/30/2021Berenberg BankReiterated RatingBuy$53.00Low
i
3/24/2021BMO Capital MarketsLower Price TargetOutperform$61.00 ➝ $59.00High
i
2/8/2021SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $52.00High
i
Rating by P. Souda at SVB Leerink LLC
1/25/2021BMO Capital MarketsBoost Price Target$48.00 ➝ $61.00Low
i
1/5/2021Berenberg BankInitiated CoverageBuy$53.00N/A
i
1/5/2021Credit Suisse GroupInitiated CoverageOutperform$52.00N/A
i
1/5/2021Stifel NicolausInitiated CoverageBuy$59.00N/A
i
1/5/2021SVB LeerinkInitiated CoverageOutperform$45.00N/A
i
Rating by P. Souda at SVB Leerink LLC
1/5/2021BMO Capital MarketsInitiated CoverageOutperform$48.00N/A
i
(Data available from 4/19/2016 forward)
AbCellera Biologics logo
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $29.82
$28.35
$30.64

50 Day Range

MA: $31.32
$23.29
$39.69

52 Week Range

Now: $29.82
$23.20
$71.91

Volume

690,700 shs

Average Volume

1,116,233 shs

Market Capitalization

$8.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AbCellera Biologics?

The following Wall Street analysts have issued reports on AbCellera Biologics in the last twelve months: Berenberg Bank, BMO Capital Markets, Credit Suisse Group AG, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ABCL.

What is the current price target for AbCellera Biologics?

5 Wall Street analysts have set twelve-month price targets for AbCellera Biologics in the last year. Their average twelve-month price target is $52.80, suggesting a possible upside of 77.1%. BMO Capital Markets has the highest price target set, predicting ABCL will reach $59.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $45.00 for AbCellera Biologics in the next year.
View the latest price targets for ABCL.

What is the current consensus analyst rating for AbCellera Biologics?

AbCellera Biologics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABCL will outperform the market and that investors should add to their positions of AbCellera Biologics.
View the latest ratings for ABCL.

What other companies compete with AbCellera Biologics?

Other companies that are similar to AbCellera Biologics include Sana Biotechnology, Abcam, Cronos Group, Genus, Abcam, BTG, Seer, MorphoSys, Nuvation Bio, ImmunityBio, Immunocore, BioAtla, Cullinan Oncology, Silverback Therapeutics and Kinnate Biopharma.

How do I contact AbCellera Biologics' investor relations team?

The company's listed phone number is 604 559 9005. The official website for AbCellera Biologics is www.abcellera.com.